FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Syndicate content

Study: Timing of new TB vaccine matters

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


A experimental vaccine for tuberculosis, called MVA85A, is more effective when give alone than in combination with other childhood shots. The next-generation vaccine is being developed by Emergent BioSolutions and Oxford University.

Each year 1.7 million people die of TB. Although there is a vaccine available, its ability to protect people as they get older fades with time. MVA85A is among a new set of vaccines in development that could prove to be more effective and safer than the Bacille Calmette-Guerin (BCG) vaccine. In a clinical trial, researchers found that MVA85A was more effective when administered alone than in combination with other vaccines. This is a significant finding because many vaccines administered in developing nations are giving in a single visit, eliminating the need for multiple trips to health clinics. This approach increases overall vaccine coverage, but in the case of MVA85A may interfere with the vaccine's effectiveness. Researchers say then need to further study how the shot will fit in with the childhood immunization schedule.

"We have a real opportunity to make sure that children are protected...against tuberculosis by introducing effective and well-timed immunization programs," noted study leader Martin Ota of the Medical Research Council Laboratories in Gambia, according to Reuters. "This can only be achieved with robust information gathered from well-conducted clinical trials."

- here's the report

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Tuberculosis   Tuberculosis Vaccine   MVA85A  


Post a comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.